Drug intelligence / Profile preview

T1695

Development stage: Phase 2
Lead developer: Théa Pharmaceuticals
Administration: Ophthalmic

Overview

T1695 is an ophthalmic suspension under clinical investigation as a potential treatment for moderate to severe vernal keratoconjunctivitis, a severe form of allergic conjunctivitis. Mechanistic and developer information is not disclosed in the available clinical trial records, and its precise molecular class, active ingredient, and pharmacologic mechanism have not been published in public databases as of this date.

Beyond the preview

Go deeper on T1695.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T1695.

Explore the full profile